Delving into the Latest Updates on Recombinant human interferon alpha-2b (Haiwang intlong) with Synapse

Overview

Basic Info

Drug Type

Interferons

Synonyms

英特龙

Target

IFNAR

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists)

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [4]

Active Indication

Condylomata AcuminataHepatitis, Viral, HumanHerpes Zoster+ [2]

Inactive Indication-

Originator Organization

Shenzhen Haiwang intlong Biotechnology Co., Ltd

Active Organization

Shenzhen Haiwang intlong Biotechnology Co., Ltd

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (01 Jan 1999),

Condylomata AcuminataHepatitis, Viral, HumanHerpes Zoster+ [2]

Regulation-

Login to view timeline

The recombinant human interferon alpha-2b (IFN-α2b) nasal drop formulation (Nasalferon) was studied as prophylaxis for SARS-CoV-2. Healthy volunteers between 19 and 80 years of age received 0.5 million international units of IFN in one drop (0.05 mL ) in each nostril, twice a day, for 10 consecutive days. The nondetection of SARS-CoV-2 by real-time polymerase chain reaction was the primary outcome variable. Several IFN-α biomarkers, including intranasal gene expression and innate immune effector activity, were increased in participants who received intranasal IFN-α2b. The study included 2,930 international travelers and 5,728 persons who were their close contacts. The subjects were treated with Nasalferon in January 2021, and 9,162 untreated travelers were included as controls. COVID-19 rate in treated subjects was significantly lower than in untreated subjects (0.05% vs. 4.84%). The proportion of travelers with COVID-19 decreased from 60.9% to 2.2% between December 2020 and February 2021. Furthermore, 1,719 tourism workers also received Nasalferon, and no cases of SARS-CoV-2 infection were detected, whereas 39 COVID-19 cases (10.6%) were reported in 367 untreated subjects. The main adverse events associated with the use of intranasal IFN-α2b were nasal congestion, headache, and rhinorrhea. Our prophylactic health interventions study demonstrates that the daily administration of Nasalferon for 10 days decreases the risk of developing COVID-19 in healthy volunteers. [Figure: see text].

01 Jan 2023·Evidence-Based Complementary and Alternative Medicine

Retracted: Clinical Observation of Reduning Combined with Recombinant Human Interferon α‐2b in the Treatment of Children with Viral Pneumonia

Author: and Alternative Medicine, Evidence-Based Complementary ; And Alternative Medicine, Evidence-Based Complementary

[This retracts the article DOI: 10.1155/2022/1739561.].

03 Aug 2022·Evidence-Based Complementary and Alternative Medicine

Influence of Lacidophilin Vaginal Capsules plus rh-IFN-α2b on Efficacy, Vaginal Microecology, and Safety of Patients with HPV Infection

Article

Author: Zhou, Hongya ; Zhu, Yan ; You, Lina ; Sun, Yan ; Xu, Jianqun

Background. Human papillomavirus (HPV) is a self-limiting disease, and there is no specific antiviral drug at present. Purpose. Here, we analyzed the influence of lacidophilin vaginal capsules plus recombinant human interferon α-2b (rh-IFN-α2b) on efficacy, vaginal microecology, and safety of patients with HPV infection. Two hundred cases of HPV infection admitted between January 2019 and December 2020 were retrospectively collected. Of them, 90 cases receiving rh-IFN-α2b intervention were assigned to the control group (CG), and 110 cases given lacidophilin vaginal capsules in addition to rh-IFN-α2b were included in the research group (RG). Baseline data, efficacy, vaginal microecology, microecological restoration recovery, and incidence of adverse events (AEs) were compared between the two groups. Results. The analyses revealed nonsignificant difference in baseline data between RG and CG, indicating comparability. In terms of efficacy, RG showed a statistically higher negative conversion ratio (NCR) than CG (57.27% vs. 47.78%), as well as an obviously higher overall response rate (ORR) (90.90% vs. 72.22%). As far as the vaginal microecology was concerned, the incidence rates of catalase-positive, sialidase-positive, abnormal microbial density, and abnormal microbial diversity of RG were significantly lower compared with CG, but no evident differences were determined in Trichomonas vaginalis-positive and Candida-positive. As for microecological restoration, RG had an obviously higher vaginal microecological recovery rate than CG (90.00% vs. 65.56%), as well as notably lower vaginal secretion pH and Nugent score. On the other hand, RG and CG showed no statistical significance in the incidence of AEs (12.73% vs. 13.33%). Conclusions. The main contributions of this study are as follows: first, it is confirmed that lacidophilin vaginal capsules plus rh-IFN-α2b has better clinical effects than rh-IFN-α2b alone in HPV-infected patients; second, it demonstrates that the combination therapy can significantly improve NCR and ORR, without increasing the incidence of AEs, and is beneficial to improve patients’ vaginal microecology and promote its restoration from the multidimensional aspects of efficacy, safety, and vaginal microecology and its recovery. Our findings provide valuable clinical evidence for the drug treatment of HPV-infected patients.

100 Deals associated with Recombinant human interferon alpha-2b (Haiwang intlong)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB05	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Condylomata Acuminata	CN	Shenzhen Haiwang intlong Biotechnology Co., Ltd	01 Jan 1999
Hepatitis, Viral, Human	CN	Shenzhen Haiwang intlong Biotechnology Co., Ltd	01 Jan 1999
Herpes Zoster	CN	Shenzhen Haiwang intlong Biotechnology Co., Ltd	01 Jan 1999
Leukemia	CN	Shenzhen Haiwang intlong Biotechnology Co., Ltd	01 Jan 1999
Lymphoma	CN	Shenzhen Haiwang intlong Biotechnology Co., Ltd	01 Jan 1999